Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Endocrinological Investigation
Published in: Journal of Endocrinological Investigation 11/2016

01-11-2016 | Opinion

Adipokines and bone metabolism: an interplay to untangle

Authors: J. Pepe, C. Cipriani, M. Cilli, L. Colangelo, S. Minisola

Published in: Journal of Endocrinological Investigation | Issue 11/2016

Login to get access

Excerpt

Recent evidence of increased fracture risk in obese patients has focused the attention on the relationship between adipose and skeletal tissue [1]. …
Literature
1.
Compston JE, Flahive J, Hosmer DW, Watts NB, Siris ES, Silverman S, Saag KG, Roux C, Rossini M, Pfeilschifter J, Nieves JW, Netelenbos JC, March L, LaCroix AZ, Hooven FH, Greenspan SL, Gehlbach SH, Díez-Pérez A, Cooper C, Chapurlat RD, Boonen S, Anderson FA Jr, Adami S, Adachi JD, Investigators GLOW (2014) Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res 29:487–493CrossRefPubMedPubMedCentral
2.
De Luis DA, Aller R, Izaola O, Bachiller R (2015) Role of rs6923761 gene variant in glucagon-like peptide 1 receptor in basal GLP-1 levels, cardiovascular risk factor and serum adipokine levels in naïve type 2 diabetic patients. J Endocrinol Invest 38:143–147CrossRefPubMed
3.
Berezin AE, Kremzer AA, Samura TA, Berezina TA, Kruzliak P (2015) Impaired immune phenotype of circulating endothelial-derived microparticles in patients with metabolic syndrome and diabetes mellitus. J Endocrinol Invest 38:865–874CrossRefPubMed
4.
Chen XX, Yang T (2015) Roles of leptin in bone metabolism and bone diseases. J Bone Miner Metab 33:474–485CrossRefPubMed
5.
Sawicka K, Krasowska D (2016) Adipokines in connective tissue diseases. Clin Exp Rheumatol (Epub ahead of print)
6.
Delfini E, Petramala L, Caliumi C, Cotesta D, De Toma G, Cavallaro G, Panzironi G, Diacinti D, Minisola S, D’ Erasmo E, Mazzuoli GF, Letizia C (2007) Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism 56:30–36CrossRefPubMed
7.
Cipriani C, Pepe J, Piemonte S, Colangelo L, Cilli M, Minisola S (2014) Vitamin d and its relationship with obesity and muscle. Int J Endocrinol 2014:841248CrossRefPubMedPubMedCentral
8.
Upala S, Sanguankeo A, Jaruvongvanich V (2015) Association between nonalcoholic fatty liver disease and bone mineral density: a systematic review and meta-analysis. J Endocrinol Invest 38:931–932CrossRefPubMed
9.
Biver E, Salliot C, Combescure C, Gossec L, Hardouin P, Legroux-Gerot I, Cortet B (2011) Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab 96:2703–2713CrossRefPubMed
10.
Arama V, Munteanu DI, Streinu Cercel A, Ion DA, Mihailescu R, Tiliscan C, Tudor AM, Arama SS (2014) Lipodystrophy syndrome in HIV treatment-multiexperienced patients: implication of resistin. J Endocrinol Invest 37:533–539CrossRefPubMed
11.
Li XP, Zeng S, Wang M, Wu XP, Liao EY (2014) Relationships between serum omentin-1, body fat mass and bone mineral density in healthy Chinese male adults in Changsha area. J Endocrinol Invest 37:991–1000CrossRefPubMed
12.
Menzel J, Di Giuseppe R, Biemann R, Aleksandrova K, Kuxhaus O, Wittenbecher C, Fritsche A, Schulze MB, Isermann B, Boeing H, Weikert C (2016) Association between omentin-1, adiponectin and bone health under consideration of osteoprotegerin as possible mediator. J Endocrinol Invest. doi:10.​1007/​s40618-016-0544-3
Metadata
Title
Adipokines and bone metabolism: an interplay to untangle
Authors
J. Pepe
C. Cipriani
M. Cilli
L. Colangelo
S. Minisola
Publication date
01-11-2016
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 11/2016
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-016-0549-y

Other articles of this Issue 11/2016

Journal of Endocrinological Investigation 11/2016 Go to the issue

Original Article

Clinical significance of ADAMTS1, ADAMTS5, ADAMTS9 aggrecanases and IL-17A, IL-23, IL-33 cytokines in polycystic ovary syndrome

Obituary

In remembrance of Professor Loredana Gandini (1957–2016)

Erratum

Erratum to: Fertility in women of late reproductive age: the role of serum anti-Müllerian hormone (AMH) levels in its assessment

Original Article

Key genes and pathways predicted in papillary thyroid carcinoma based on bioinformatics analysis

Original Article

Association between omentin-1, adiponectin and bone health under consideration of osteoprotegerin as possible mediator

Original Article

Association between bone mineral density and nonalcoholic fatty liver disease in Korean adults
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits